日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINER

在心血管试验中保持试验终点特异性和死亡原因归因:来自 MARINER 研究的启示

Hogan, Shea E; Canonico, Mario Enrico; King, Robert W; Low Wang, Cecilia C; Nehler, Mark R; Parr, Jessica; Rogers, R Kevin; Lu, Wentao; Albanese, John; Barnathan, Elliot S; Spyropoulos, Alex C; Douketis, James D; Bonaca, Marc P; Capell, Warren H

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial

利伐沙班在接受外周动脉血运重建术后患者中的定量获益-风险评估:VOYAGER PAD试验

Yuan, Zhong; Levitan, Bennett; Deng, Hsiaowei; Szarek, Michael; Bauersachs, Rupert M; Berkowitz, Scott D; Haskell, Lloyd; Barnathan, Elliot S; Bonaca, Marc P

Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

利伐沙班用于院前 COVID-19 患者的抗血栓预防:两项安慰剂对照试验的荟萃分析

Hsia, Judith; Spyropoulos, Alex C; Piazza, Gregory; Weng, Stephen; Dunne, Michael W; Lipardi, Concetta; Barnathan, Elliot S; Bonaca, Marc P

Primary thromboprophylaxis in ambulatory symptomatic patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

针对门诊有症状的 COVID-19 患者的一级血栓预防:随机对照试验的系统评价和荟萃分析

Di Vece, Davide; Valgimigli, Marco; Barnathan, Elliot; Connors, Jean M; Cools, Frank; Held, Ulrike; Kakkar, Ajay K; Piazza, Gregory; Spirk, David; Virdone, Saverio; Kucher, Nils; Barco, Stefano

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

利伐沙班预防新冠肺炎门诊患者血栓事件、住院和死亡:一项随机临床试验

Piazza, Gregory; Spyropoulos, Alex C; Hsia, Judith; Goldin, Mark; Towner, William J; Go, Alan S; Bull, Todd M; Weng, Stephen; Lipardi, Concetta; Barnathan, Elliot S; Bonaca, Marc P

Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease

更新利伐沙班在患有或有血栓栓塞性疾病风险患者中的肾脏剂量建议

Volkl, Albert A; Moore, Kenneth Todd; Haskell, Lloyd; Barnathan, Elliot S

Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

急性冠脉综合征患者行冠状动脉支架置入术后早期、晚期和极晚期支架血栓形成的相关因素:来自 ATLAS ACS 2-TIMI 51 试验的分析

Chi, Gerald; AlKhalfan, Fahad; Lee, Jane J; Montazerin, Sahar Memar; Fitzgerald, Clara; Korjian, Serge; Omar, Wally; Barnathan, Elliot; Plotnikov, Alexei; Gibson, C Michael

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness

利伐沙班用于住院后长期血栓预防的获益风险评估

Raskob, Gary E; Ageno, Walter; Albers, Gregory; Elliott, C Gregory; Halperin, Jonathan; Maynard, Gregory; Steg, Philippe Gabriel; Weitz, Jeffrey I; Albanese, John; Yuan, Zhong; Levitan, Bennett; Lu, Wentao; Suh, Eun Young; Spiro, Theodore; Lipardi, Concetta; Barnathan, Elliot S; Spyropoulos, Alex C

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial

利伐沙班联合阿司匹林用于急性重症内科患者的长期血栓预防:来自 MARINER 试验的启示

Spyropoulos, Alex C; Goldin, Mark; Ageno, Walter; Albers, Gregory W; Elliott, C Gregory; Hiatt, William R; Halperin, Jonathan L; Maynard, Gregory; Steg, P Gabriel; Weitz, Jeffrey I; Spiro, Theodore E; Lu, Wentao; Marsigliano, Jessica; Raskob, Gary E; Barnathan, Elliot S

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study

住院心力衰竭患者的延长血栓预防:MAGELLAN 研究的事后分析

Spyropoulos, Alex C; Raskob, Gary E; Spiro, Theodore E; Lu, Wentao; De Sanctis, Yoriko; Albanese, John; Mebazaa, Alexandre; Barnathan, Elliot S